Just been reading through the latest (and 2nd) report from the UK medicines regulatory body, the MHRA on monitoring of advertisements for medicines. It makes for interesting reading and is full of graphs & comparative data to show their performance (targets anyone?). Some points worth noting – see page 18 – on advertising for new medicines, especially the use of clinical study information & situations where new comparative data varies from the current SPC.
Check it out on their website under News centre. www.mhra.gov.uk. They also mention the Information Accreditation Scheme which they encourage companies to sign up to for non- promotional disease awareness information or patient-orientated support.